VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

AAN 2022 | Assessing remibrutinib in patients with relapsing MS

Xavier Montalban, MD, PhD, BA, Vall d’Hebron University Hospital, Barcelona, Spain, provides an overview of the Phase III REMODEL I and II trials (NCT05147220) of remibrutinib, a reversible BTK inhibitor, in patients with relapsing multiple sclerosis (MS). The two identical trials will assess the safety and tolerability of remibrutinib by comparing the BTK inhibitor with teriflunomide. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.